COHANCECohance Lifesciences

₹742.75-0.01%

Market Cap

₹28,376.92 Cr

Stock P/E

110.86

ROCE

18.44%

ROE

14.20%

Book Value

₹45.45

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Foreign Investors

Domestic Investors

Public

From Last Concall

POSITIVES

•
FY ’25 ended with 9% YoY revenue growth and EBITDA margins of 34%, signaling solid growth.
•
Created a $335 million integrated technology-led platform revenue company, indicating disciplined execution.

NEGATIVES

•
EBITDA margins expected to dip to the low 30s in FY26 (temporary).
•
Q1 FY26 is expected to be muted due to shipment timings and inventory adjustments.

Peers Summary

Deep Value Pick

Cohance Lifesciences Ltd. demonstrates strong profitability with a substantial ROE, but its high PE ratio indicates it may be overvalued compared to peers. However, it has the lowest debt levels, making it a safer investment compared to others with higher debt ratios. Among its peers, Dr. Reddy's Laboratories stands out for its strong profitability and low valuation metrics, making it a potential value pick.

Key Points

• Cohance Lifesciences has the lowest debt to equity ratio (0.0465), indicating low financial risk.
• Dr. Reddy's Laboratories offers strong profitability with a PE ratio of 15.50, making it a highly attractive value pick.
• Mankind Pharma shows the highest revenue growth YoY (18.12%) and 3-Year (155.25%), indicating excellent growth potential.

Top Performers

Dr. Reddy's Laboratories Ltd.

Strong profitability metrics with high ROE and low valuation, making it a solid investment.

Mankind Pharma Ltd.

Exceptional growth trajectory with the highest revenue growth and strong profitability.

Explore

Watchlists

Command Palette